[Translation] A phase 1, randomized, double-blind, placebo to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 (Bentracimab) with and without ticagrelor pretreatment in healthy Chinese volunteers Controlled, single-dose escalation study
本研究的主要目的是针对中国受试者评估以渐增型单一剂量方式经静脉 (IV) 给予 PB2452(伴或不伴替格瑞洛)的安全性和耐受性,此外通过 VerifyNow P2Y12 测定法测量 P2Y12 反应单位 (PRU),评估 PB2452 单次剂量递增给药对替格瑞洛抗血小板活性的影响。
[Translation] The primary objective of this study was to evaluate the safety and tolerability of intravenous (IV) administration of PB2452 (with or without ticagrelor) in escalating single doses in Chinese subjects, in addition to the use of the VerifyNow P2Y12 assay. P2Y12 response units (PRUs) were measured to assess the effect of single escalating doses of PB2452 on the antiplatelet activity of ticagrelor.